A Phase I/II trial by Japan’s Kyoto University Hospital and CiRA team has demonstrated outcomes with allogeneic iPS ...

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...

A subgroup of participants with low or no tau -- below 1.06 standardized uptake value ratio (SUVR) on PET ... the open-label extension study who received lecanemab. Amyloid-related imaging ...

AUA annual meeting featured a kidney cancer session and a presentation by Dr. Pratik Kanabur discussing a cost-effectiveness analysis of 89 Zr-girentuximab PET-CT (TLX250) to guide management of small ...

In a first-of-its-kind human trial, researchers transplanted iPS-cell-derived dopaminergic progenitors into patients with ...

Here is the status of major bills following the end of Hawaii’s annual 60-day legislative session on Friday. The bills listed ...

Clarity, along with most Aussie biotech, has been caught in a double whirlwind: a sharp sell-off in US healthcare stocks and ...

Minerals Technologies Inc. ( NYSE: MTX) Q1 2025 Earnings Conference Call April 25, 2025 11:00 AM ET Daniel Moore - CJS Securities Mike Harrison - Seaport Research Partners David Silver - C.L. King ...

The Union government’s latest offensive in Chhattisgarh’s Bastar region, launched under ‘Operation Kagar’, intensifies the ...

MELBOURNE, Australia, April 29, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET [1] imaging agent ...

A PET scan is a test that creates 3 dimensional (3D ... you can call the Cancer Research UK information nurses on freephone 0808 800 4040. The lines are open from 9am to 5pm, Monday to Friday.

MELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET 1 imaging agent ... a ...